Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Open Angle Glaucoma
Interventions: Micropulse Laser Trabeculoplasty, Selective Laser Trabeculoplasty; Device
Lead sponsor: David Belyea; Other
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: High Dose Device, Low Dose Device, Placebo Device; Drug · Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more

Conditions: Ocular Hypertension
Interventions: C-KAD Ophthalmic Solution; Drug
Lead sponsor: Chakshu Research, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypertension
Interventions: TRANSLATE; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension
Interventions: Ramipril; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension, Angina, Diabetes
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 39,481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: No. Little Rock, Washington

Conditions: Pulmonary Arterial Hypertension
Interventions: Blood draw; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Audit and Feedback, Pharmacist E-Detailing; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
Interventions: Nicotinamide riboside; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 35 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Venous Hypertension With Ulcer
Interventions: Standard Multi-layered Compression dressing, Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin); Procedure
Lead sponsor: Solsys Medical LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more

Conditions: Glaucoma
Interventions: Prednisolone 1%, Ketorolac, Artificial Tears; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions: Fish Oil, Flaxseed Oil, Placebo; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: PAH
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Aurora, Colorado • Weston, Florida • Baltimore, Maryland + 5 more

Conditions: Sickle Cell Disease, Obesity, Childhood, Hypertension, Hyperlipidemia in Children, Hyperglycemia
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 10 Years to 19 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hemodialysis Complication, Fluid Overload, Dialysis Disequilibrium, Intra-dialytic Hypotension, Hypertension
Interventions: Dialysate Sodium Lowering; Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperlipidemias, Diabetes, Depression, Pediatric Asthma, Hypertension
Interventions: WE CARE SDOH System, Standard Pediatric Care; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: Not listed
Enrollment: 68,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Worcester, Massachusetts

Conditions: Glaucoma
Interventions: Latanoprost 0.005%; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Kidney Diseases
Interventions: Pioglitazone, Placebo; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 35 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Hypertension
Interventions: Renal Denervation; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 2 more

Conditions: Obesity
Interventions: Lorcaserin 10 mg BID, Matching Placebo BID; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma

Safety and Efficacy of a Glaucoma Drug Delivery System

An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension

Improving Diabetes in Primary Care (IMPACT)

Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions

Improving Service Delivery Through Access Points

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension

Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing

Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Standard Compression Therapy With/Without Application of Skin Allograft (Theraskin) for Venous Leg Ulcer Treatment

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

Steroids After Laser Trabeculoplasty for Glaucoma

Effects of Omega-3 Fatty Acids on Markers of Inflammation

Pulmonary Hypertension and Imatinib

Obesity in Pediatric Sickle Cell Disease: A New Phenomenon

Dialysate Sodium Lowering Trial

Social Needs Screening and Chronic Diseases Study (WE CARE)

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management